{
    "mainTopic": {
        "title": "Lipid Lowering Drugs",
        "content_info": "The lecture handouts come with a lot of detailed information that is sufficient to cover the whole topic",
        "subTopics": [
            {
                "title": "Overview of atherosclerosis",
                "quizzes": [
                    {
                        "question": "Atherosclerosis is primarily characterized by which of the following pathological processes within the arterial wall?",
                        "goodAnswer": "Atherosclerosis is characterized by chronic inflammation of the arterial wall, driven predominantly by the accumulation of lipids, particularly cholesterol, leading to plaque formation and subsequent vascular remodeling.",
                        "wrongAnswer_1": "Atherosclerosis is defined by acute inflammation of the venous wall, triggered by high glucose levels, resulting in the deposition of calcium and eventual arterial stiffening.",
                        "wrongAnswer_2": "Atherosclerosis is characterized by acute vasoconstriction of the arterial wall, primarily due to sodium accumulation, leading to endothelial dysfunction and platelet aggregation without significant lipid involvement.",
                        "wrongAnswer_3": "Atherosclerosis is characterized by chronic vasoconstriction of the venous wall, initiated by elevated triglyceride levels, causing smooth muscle proliferation and the formation of fibrous plaques lacking lipid cores.",
                        "wrongAnswer_4": "Atherosclerosis is defined by chronic inflammation of the venous wall, driven by the accumulation of triglycerides, leading to thrombus formation and subsequent vascular dilation."
                    },
                    {
                        "question": "Initiation of atherosclerosis is most strongly linked to which of the following cellular events in the arterial intima?",
                        "goodAnswer": "The initiation of atherosclerosis is primarily linked to endothelial dysfunction in the arterial intima, manifesting as increased permeability to lipoproteins, enhanced leukocyte adhesion molecule expression, and subsequent monocyte infiltration and differentiation into macrophages.",
                        "wrongAnswer_1": "The initiation of atherosclerosis is primarily linked to smooth muscle cell activation in the arterial media, characterized by phenotypic switching from contractile to synthetic state, migration into the intima, and excessive extracellular matrix production.",
                        "wrongAnswer_2": "The initiation of atherosclerosis is primarily linked to adventitial fibroblast proliferation in the arterial adventitia, characterized by increased collagen type III synthesis, neovascularization, and outward arterial remodeling to maintain lumen size.",
                        "wrongAnswer_3": "The initiation of atherosclerosis is primarily linked to platelet activation and aggregation at sites of turbulent blood flow in the arterial lumen, leading to microthrombus formation and subsequent endothelial denudation and dysfunction.",
                        "wrongAnswer_4": "The initiation of atherosclerosis is primarily linked to mast cell degranulation in the arterial intima, releasing histamine and other vasoactive mediators that promote acute inflammation and neutrophil recruitment to the endothelial layer."
                    },
                    {
                        "question": "Which of the following best describes the role of macrophages in the progression of atherosclerotic plaques?",
                        "goodAnswer": "Macrophages play a critical role in plaque progression by internalizing modified LDL, transforming into foam cells, and releasing inflammatory mediators and matrix metalloproteinases that contribute to plaque instability and rupture.",
                        "wrongAnswer_1": "Macrophages primarily function in plaque regression by degrading accumulated cholesterol, transforming into smooth muscle cells, and releasing anti-inflammatory cytokines and tissue inhibitors of metalloproteinases that enhance plaque stability.",
                        "wrongAnswer_2": "Macrophages play a minor role in plaque progression by internalizing native LDL, transforming into T-cells, and releasing pro-inflammatory cytokines and growth factors that contribute to plaque calcification and stenosis.",
                        "wrongAnswer_3": "Macrophages primarily function in plaque stabilization by synthesizing collagen, transforming into fibroblasts, and releasing anti-inflammatory mediators and growth factors that contribute to plaque fibrosis and reduced inflammation.",
                        "wrongAnswer_4": "Macrophages play a critical role in plaque progression by internalizing HDL, transforming into foam cells, and releasing anti-inflammatory mediators and matrix metalloproteinases that contribute to plaque stability and reduced inflammation."
                    },
                    {
                        "question": "Advanced atherosclerotic plaques are characterized by several features that increase the risk of thrombotic events. Which of the following is considered the most critical determinant of plaque vulnerability?",
                        "goodAnswer": "The vulnerability of advanced atherosclerotic plaques to rupture and subsequent thrombosis is primarily determined by plaque composition, specifically a thin fibrous cap with reduced smooth muscle cell and collagen content overlying a large lipid-rich necrotic core infiltrated by activated macrophages and T-lymphocytes.",
                        "wrongAnswer_1": "The vulnerability of advanced atherosclerotic plaques to rupture and subsequent thrombosis is primarily determined by plaque size and lumen obstruction, with larger plaques causing greater hemodynamic stress and flow disturbances, leading to increased shear stress and endothelial erosion.",
                        "wrongAnswer_2": "The vulnerability of advanced atherosclerotic plaques to rupture and subsequent thrombosis is primarily determined by the degree of plaque calcification, with heavily calcified plaques being more prone to fracture and fissuring, initiating platelet adhesion and thrombus formation.",
                        "wrongAnswer_3": "The vulnerability of advanced atherosclerotic plaques to rupture and subsequent thrombosis is primarily determined by the extent of vasa vasorum neovascularization within the plaque, with increased intraplaque hemorrhage and erythrocyte accumulation contributing to plaque instability.",
                        "wrongAnswer_4": "The vulnerability of advanced atherosclerotic plaques to rupture and subsequent thrombosis is primarily determined by the presence of endothelial denudation and ulceration, exposing subendothelial matrix components that trigger platelet activation and the coagulation cascade, irrespective of plaque composition."
                    }
                ]
            },
            {
                "title": "Transmembrane receptors on mammalian cells, Apolipoproteins, sterols and lipoprotein cycles",
                "quizzes": [
                    {
                        "question": "The LDL receptor, a crucial transmembrane protein, mediates the cellular uptake of LDL particles. Which of the following molecular mechanisms accurately describes the LDL receptor's function and regulation?",
                        "goodAnswer": "The LDL receptor is a cell surface glycoprotein that binds apolipoprotein B-100 (ApoB-100) on LDL particles with high affinity, initiating clathrin-mediated endocytosis and internalization of LDL-receptor complexes; its expression is transcriptionally regulated by intracellular cholesterol levels via sterol regulatory element-binding protein-2 (SREBP-2) activation.",
                        "wrongAnswer_1": "The LDL receptor is an intracellular endoplasmic reticulum protein that binds apolipoprotein A-I (ApoA-I) on HDL particles with low affinity, initiating caveolin-mediated endocytosis and internalization of HDL-receptor complexes; its expression is post-translationally regulated by extracellular cholesterol levels via liver X receptor (LXR) activation.",
                        "wrongAnswer_2": "The LDL receptor is a mitochondrial outer membrane protein that binds apolipoprotein C-II (ApoC-II) on VLDL particles with moderate affinity, initiating macropinocytosis and internalization of VLDL-receptor complexes; its expression is epigenetically regulated by intracellular triglyceride levels via peroxisome proliferator-activated receptor gamma (PPAR-gamma) activation.",
                        "wrongAnswer_3": "The LDL receptor is a nuclear membrane protein that binds apolipoprotein E (ApoE) on chylomicron remnants with variable affinity, initiating phagocytosis and internalization of remnant-receptor complexes; its expression is translationally regulated by extracellular glucose levels via carbohydrate-responsive element-binding protein (ChREBP) activation.",
                        "wrongAnswer_4": "The LDL receptor is a lysosomal membrane protein that binds apolipoprotein B-48 (ApoB-48) on IDL particles with no affinity, initiating autophagy and degradation of IDL particles; its expression is constitutively expressed and not regulated by cellular lipid levels."
                    },
                    {
                        "question": "Apolipoproteins are essential protein components of lipoproteins, playing critical roles in lipoprotein metabolism. Which of the following apolipoproteins is correctly matched with its primary function?",
                        "goodAnswer": "Apolipoprotein B-100 (ApoB-100) is crucial for the structural integrity of VLDL, IDL, and LDL particles, facilitating their assembly and secretion from the liver, and acting as the primary ligand for the LDL receptor, mediating hepatic and peripheral cellular uptake of LDL.",
                        "wrongAnswer_1": "Apolipoprotein A-I (ApoA-I) is essential for the structural integrity of chylomicrons and nascent HDL particles, facilitating their assembly and secretion from the intestine, and acting as the primary ligand for the scavenger receptor class B type 1 (SR-BI), mediating selective hepatic uptake of HDL cholesterol esters.",
                        "wrongAnswer_2": "Apolipoprotein C-II (ApoC-II) is essential for the structural integrity of IDL and mature HDL particles, facilitating their assembly and secretion from the liver, and acting as the primary co-activator of lipoprotein lipase (LPL), mediating hydrolysis of triglycerides in VLDL and chylomicrons in the capillaries of adipose tissue and muscle.",
                        "wrongAnswer_3": "Apolipoprotein E (ApoE) is essential for the structural integrity of LDL and VLDL remnants, facilitating their assembly and secretion from the liver, and acting as the primary ligand for the VLDL receptor (VLDLR) and LDL receptor-related protein (LRP), mediating hepatic uptake of chylomicron and VLDL remnants.",
                        "wrongAnswer_4": "Apolipoprotein B-48 (ApoB-48) is essential for the structural integrity of nascent chylomicrons, facilitating their assembly and secretion from the intestine, and acting as the primary inhibitor of cholesterol ester transfer protein (CETP), mediating the transfer of cholesteryl esters from HDL to VLDL and LDL."
                    },
                    {
                        "question": "Cholesterol homeostasis is tightly regulated through various pathways, including de novo synthesis and dietary uptake.  Which of the following accurately describes a key regulatory step in cholesterol biosynthesis?",
                        "goodAnswer": "The rate-limiting and committed step in de novo cholesterol biosynthesis is the conversion of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonate, catalyzed by HMG-CoA reductase; the activity and expression of HMG-CoA reductase are feedback-inhibited by intracellular cholesterol levels and pharmacologically targeted by statin drugs.",
                        "wrongAnswer_1": "The rate-limiting and committed step in de novo cholesterol biosynthesis is the esterification of free cholesterol to cholesteryl esters, catalyzed by acyl-CoA cholesterol acyltransferase (ACAT); the activity and expression of ACAT are feedback-inhibited by intracellular fatty acid levels and pharmacologically targeted by fibrate drugs.",
                        "wrongAnswer_2": "The rate-limiting and committed step in de novo cholesterol biosynthesis is the transfer of cholesteryl esters from HDL to VLDL and LDL, catalyzed by cholesterol ester transfer protein (CETP); the activity and expression of CETP are feedback-inhibited by intracellular triglyceride levels and pharmacologically targeted by niacin drugs.",
                        "wrongAnswer_3": "The rate-limiting and committed step in de novo cholesterol biosynthesis is the esterification of free cholesterol in HDL particles, catalyzed by lecithin-cholesterol acyltransferase (LCAT); the activity and expression of LCAT are feedback-inhibited by intracellular phospholipid levels and pharmacologically targeted by ezetimibe drugs.",
                        "wrongAnswer_4": "The rate-limiting and committed step in de novo cholesterol biosynthesis is the transcriptional activation of genes involved in cholesterol uptake, mediated by sterol regulatory element-binding protein-2 (SREBP-2); the activity and expression of SREBP-2 are feedback-inhibited by intracellular glucose levels and pharmacologically targeted by bile acid sequestrants."
                    },
                    {
                        "question": "The reverse cholesterol transport (RCT) pathway plays a crucial role in removing excess cholesterol from peripheral tissues and delivering it to the liver for excretion. Which of the following accurately outlines the key steps in RCT?",
                        "goodAnswer": "Reverse cholesterol transport (RCT) initiates with ATP-binding cassette transporter A1 (ABCA1)-mediated efflux of free cholesterol and phospholipids from peripheral cells to lipid-poor apolipoproteins, forming nascent HDL -> Lecithin-cholesterol acyltransferase (LCAT) esterifies free cholesterol within HDL, forming mature HDL -> Cholesteryl ester transfer protein (CETP) mediates transfer of cholesteryl esters from HDL to VLDL and LDL in exchange for triglycerides -> Hepatic uptake of cholesterol and cholesteryl esters occurs via scavenger receptor class B type 1 (SR-BI) and LDL receptor.",
                        "wrongAnswer_1": "Reverse cholesterol transport (RCT) initiates with scavenger receptor class B type 1 (SR-BI)-mediated efflux of cholesteryl esters from peripheral cells to nascent VLDL -> Acyl-CoA cholesterol acyltransferase (ACAT) esterifies free cholesterol within VLDL, forming mature VLDL -> Microsomal triglyceride transfer protein (MTP) mediates transfer of cholesteryl esters from VLDL to LDL in exchange for phospholipids -> Intestinal uptake of cholesterol and cholesteryl esters occurs via Niemann-Pick C1-Like 1 (NPC1L1) and LDL receptor.",
                        "wrongAnswer_2": "Reverse cholesterol transport (RCT) initiates with Niemann-Pick C1-Like 1 (NPC1L1)-mediated efflux of free cholesterol from peripheral cells to nascent LDL -> HMG-CoA reductase esterifies free cholesterol within LDL, forming mature LDL -> ATP-binding cassette subfamily G member 5/8 (ABCG5/G8) mediates transfer of cholesteryl esters from LDL to HDL in exchange for triglycerides -> Renal excretion of cholesterol and cholesteryl esters occurs via ATP-binding cassette transporter A1 (ABCA1) and scavenger receptor class B type 1 (SR-BI).",
                        "wrongAnswer_3": "Reverse cholesterol transport (RCT) initiates with LDL receptor-related protein (LRP)-mediated efflux of triglycerides from peripheral cells to nascent chylomicrons -> Apolipoprotein C-II (ApoC-II) esterifies free cholesterol within chylomicrons, forming mature chylomicrons -> Lipoprotein lipase (LPL) mediates transfer of cholesteryl esters from chylomicrons to VLDL in exchange for free fatty acids -> Muscle uptake of cholesterol and cholesteryl esters occurs via LDL receptor and ATP-binding cassette transporter A1 (ABCA1).",
                        "wrongAnswer_4": "Reverse cholesterol transport (RCT) initiates with cholesterol ester transfer protein (CETP)-mediated efflux of cholesteryl esters from peripheral cells to nascent IDL -> Apolipoprotein B-48 (ApoB-48) esterifies free cholesterol within IDL, forming mature IDL -> Hepatic lipase (HL) mediates transfer of cholesteryl esters from IDL to HDL in exchange for phospholipids -> Adipose tissue uptake of cholesterol and cholesteryl esters occurs via scavenger receptor class B type 1 (SR-BI) and Niemann-Pick C1-Like 1 (NPC1L1)."
                    }
                ]
            },
            {
                "title": "Lipid lowering drugs",
                "quizzes": [
                    {
                        "question": "Statins are a cornerstone in the pharmacological management of hyperlipidemia and atherosclerosis. What is the primary mechanism of action of statin drugs in lowering LDL cholesterol levels?",
                        "goodAnswer": "Statins primarily lower LDL cholesterol levels by competitively inhibiting 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase), the rate-limiting enzyme in hepatic cholesterol biosynthesis, leading to decreased intracellular cholesterol concentration and subsequent upregulation of LDL receptor expression on hepatocytes.",
                        "wrongAnswer_1": "Statins primarily lower LDL cholesterol levels by directly inhibiting acyl-CoA cholesterol acyltransferase (ACAT) in hepatocytes, the enzyme responsible for intracellular cholesterol esterification, leading to increased intracellular free cholesterol and accelerated cholesterol efflux via ABCA1 transporters.",
                        "wrongAnswer_2": "Statins primarily lower LDL cholesterol levels by selectively inhibiting cholesterol ester transfer protein (CETP) in plasma, the protein that mediates the transfer of cholesteryl esters from HDL to VLDL and LDL, leading to decreased cholesterol transfer and reduced LDL particle formation.",
                        "wrongAnswer_3": "Statins primarily lower LDL cholesterol levels by directly inhibiting lecithin-cholesterol acyltransferase (LCAT) in plasma, the enzyme that esterifies free cholesterol in HDL, leading to decreased HDL cholesterol levels and enhanced catabolism of LDL particles through alternative pathways.",
                        "wrongAnswer_4": "Statins primarily lower LDL cholesterol levels by competitively inhibiting sterol regulatory element-binding protein-2 (SREBP-2) activation in hepatocytes, the transcription factor that upregulates genes involved in cholesterol uptake, leading to decreased LDL receptor expression and reduced LDL clearance from circulation."
                    },
                    {
                        "question": "Ezetimibe is another class of lipid-lowering drugs used to manage hypercholesterolemia. What is the principal mechanism by which ezetimibe reduces LDL cholesterol levels?",
                        "goodAnswer": "Ezetimibe reduces LDL cholesterol levels primarily by selectively inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein located on the brush border of enterocytes in the small intestine, thereby reducing intestinal absorption of dietary and biliary cholesterol and consequently decreasing LDL cholesterol levels.",
                        "wrongAnswer_1": "Ezetimibe reduces LDL cholesterol levels primarily by activating peroxisome proliferator-activated receptor alpha (PPAR-alpha) in the liver, thereby increasing hepatic fatty acid oxidation and reducing VLDL production, which indirectly leads to decreased LDL cholesterol levels due to reduced VLDL precursor availability.",
                        "wrongAnswer_2": "Ezetimibe reduces LDL cholesterol levels primarily by inhibiting bile acid reabsorption in the ileum through binding to the apical sodium-dependent bile acid transporter (ASBT), thereby increasing bile acid synthesis from cholesterol and consequently lowering hepatic cholesterol content and LDL production.",
                        "wrongAnswer_3": "Ezetimibe reduces LDL cholesterol levels primarily by activating liver X receptor (LXR) in macrophages and hepatocytes, thereby promoting cholesterol efflux from peripheral cells and reverse cholesterol transport, which secondarily reduces LDL cholesterol levels by enhancing cholesterol removal from the body.",
                        "wrongAnswer_4": "Ezetimibe reduces LDL cholesterol levels primarily by inhibiting microsomal triglyceride transfer protein (MTP) in the liver and intestine, thereby reducing the assembly and secretion of both VLDL and chylomicrons, consequently lowering circulating triglyceride levels and indirectly affecting LDL cholesterol concentrations."
                    },
                    {
                        "question": "PCSK9 inhibitors represent a newer class of lipid-lowering drugs with significant efficacy in reducing LDL cholesterol. How do PCSK9 inhibitors achieve their LDL-lowering effect?",
                        "goodAnswer": "PCSK9 inhibitors reduce LDL cholesterol levels by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease that promotes LDL receptor degradation in lysosomes; by inhibiting PCSK9, these drugs increase LDL receptor recycling to the cell surface, enhancing LDL clearance from the circulation.",
                        "wrongAnswer_1": "PCSK9 inhibitors reduce LDL cholesterol levels by activating ATP-binding cassette transporter A1 (ABCA1) in hepatocytes and macrophages, a transmembrane protein that mediates cholesterol efflux, leading to increased reverse cholesterol transport and reduced hepatic cholesterol content, indirectly lowering LDL levels.",
                        "wrongAnswer_2": "PCSK9 inhibitors reduce LDL cholesterol levels by inhibiting cholesterol ester transfer protein (CETP) in plasma, a protein that facilitates the exchange of cholesteryl esters between lipoproteins, leading to increased HDL cholesterol and decreased transfer of cholesterol to LDL precursors.",
                        "wrongAnswer_3": "PCSK9 inhibitors reduce LDL cholesterol levels by activating lipoprotein lipase (LPL) in capillaries, an enzyme that hydrolyzes triglycerides in VLDL and chylomicrons, leading to decreased VLDL and IDL production and consequently reduced formation of LDL from VLDL catabolism.",
                        "wrongAnswer_4": "PCSK9 inhibitors reduce LDL cholesterol levels by inhibiting microsomal triglyceride transfer protein (MTP) in hepatocytes, a protein required for VLDL assembly and secretion, leading to decreased hepatic VLDL output and reduced conversion of VLDL to LDL in the circulation."
                    },
                    {
                        "question": "Fibrates are primarily used to treat hypertriglyceridemia. What is the main mechanism through which fibrates lower triglyceride levels and potentially impact other lipid parameters?",
                        "goodAnswer": "Fibrates primarily lower triglyceride levels by activating peroxisome proliferator-activated receptor alpha (PPAR-alpha), a nuclear receptor that increases the transcription of genes encoding lipoprotein lipase (LPL), apolipoprotein A-I, and fatty acid oxidation enzymes, leading to enhanced triglyceride hydrolysis and clearance, modestly increased HDL, and variable effects on LDL.",
                        "wrongAnswer_1": "Fibrates primarily lower triglyceride levels by inhibiting 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase), the rate-limiting enzyme in cholesterol synthesis, leading to reduced hepatic cholesterol production and decreased VLDL assembly, consequently lowering both triglyceride and LDL levels, while significantly decreasing HDL due to pleiotropic effects.",
                        "wrongAnswer_2": "Fibrates primarily lower triglyceride levels by inhibiting Niemann-Pick C1-Like 1 (NPC1L1) protein in the small intestine, reducing intestinal cholesterol absorption and consequently decreasing chylomicron production, which indirectly lowers triglyceride and LDL levels but has minimal impact on HDL cholesterol.",
                        "wrongAnswer_3": "Fibrates primarily lower triglyceride levels by activating liver X receptor (LXR) in hepatocytes and macrophages, a nuclear receptor that promotes cholesterol efflux and reverse cholesterol transport, leading to reduced triglyceride levels indirectly through improved lipoprotein metabolism and significantly increased HDL levels.",
                        "wrongAnswer_4": "Fibrates primarily lower triglyceride levels by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease that degrades LDL receptors, leading to enhanced LDL clearance and indirectly reducing triglyceride levels through increased hepatic uptake of VLDL remnants and accelerated VLDL catabolism."
                    }
                ]
            },
            {
                "title": "Investigational treatments of atherosclerosis and non-drug treatment: LDL apheresis",
                "quizzes": [
                    {
                        "question": "LDL apheresis is a non-pharmacological treatment for severe hypercholesterolemia. Which of the following best describes the principle and application of LDL apheresis?",
                        "goodAnswer": "LDL apheresis is an extracorporeal blood purification technique that selectively removes LDL particles, including lipoprotein(a), from plasma via specific filters or immunoabsorption columns, primarily indicated for patients with homozygous familial hypercholesterolemia or severe heterozygous FH unresponsive to maximal drug therapy.",
                        "wrongAnswer_1": "LDL apheresis is an intravenous enzyme replacement therapy that selectively degrades LDL particles in the bloodstream using recombinant lipoprotein lipase, primarily used in patients with heterozygous familial hypercholesterolemia who are intolerant to statin and ezetimibe combination therapy.",
                        "wrongAnswer_2": "LDL apheresis is an oral medication containing plant sterols and stanols that selectively inhibits LDL production in the liver by competing with cholesterol for absorption, primarily used in patients with polygenic hypercholesterolemia and mild to moderate LDL elevations as an adjunct to lifestyle modifications.",
                        "wrongAnswer_3": "LDL apheresis is a surgical procedure involving percutaneous transluminal coronary angioplasty (PTCA) that selectively removes atherosclerotic plaques from coronary arteries, primarily used in patients with advanced symptomatic atherosclerosis and acute coronary syndromes requiring immediate revascularization.",
                        "wrongAnswer_4": "LDL apheresis is a dietary intervention consisting of a very-low-fat, high-fiber diet that selectively reduces LDL absorption from the intestine and hepatic synthesis, primarily used in patients with secondary hypercholesterolemia due to lifestyle factors and metabolic syndrome as a first-line treatment strategy."
                    },
                    {
                        "question": "Several investigational treatments for atherosclerosis are under development, targeting various pathways involved in disease progression. Which of the following represents a promising therapeutic target currently under investigation for atherosclerosis?",
                        "goodAnswer": "Inhibition of lipoprotein(a) [Lp(a)] synthesis and assembly using antisense oligonucleotides or small interfering RNAs is a promising therapeutic target under investigation, aiming to reduce genetically determined elevated Lp(a) levels, a causal risk factor for cardiovascular disease independent of LDL-C.",
                        "wrongAnswer_1": "Activation of cholesteryl ester transfer protein (CETP) using small molecule agonists is a promising therapeutic target under investigation, aiming to increase CETP activity to enhance reverse cholesterol transport, promote HDL-mediated cholesterol efflux, and consequently reduce LDL cholesterol and atherosclerotic burden.",
                        "wrongAnswer_2": "Inhibition of ATP-binding cassette transporter A1 (ABCA1) using small molecule inhibitors is a promising therapeutic target under investigation, aiming to reduce ABCA1-mediated cholesterol efflux from macrophages to nascent HDL, promote macrophage foam cell formation, and enhance plaque stabilization by increasing cellular cholesterol retention.",
                        "wrongAnswer_3": "Activation of squalene synthase, a key enzyme in cholesterol biosynthesis, using gene therapy vectors is a promising therapeutic target under investigation, aiming to increase squalene synthase activity to enhance cholesterol production, promote LDL receptor degradation via feedback mechanisms, and reduce circulating LDL levels.",
                        "wrongAnswer_4": "Inhibition of microsomal triglyceride transfer protein (MTP) using gene editing technologies is a promising therapeutic target under investigation, aiming to reduce MTP activity in the liver and intestine to increase VLDL and chylomicron secretion, promote hypertriglyceridemia, and indirectly reduce LDL particle concentrations."
                    },
                    {
                        "question": "Gene therapy approaches are being explored as potential treatments for hyperlipidemia and atherosclerosis. Which of the following gene therapy strategies is currently under investigation for lowering LDL cholesterol?",
                        "goodAnswer": "Gene therapy to enhance LDL receptor expression in hepatocytes using viral vectors, such as adeno-associated virus (AAV), is under investigation to increase LDL receptor density on the liver cell surface, thereby promoting enhanced hepatic LDL uptake and clearance from the circulation in patients with familial hypercholesterolemia.",
                        "wrongAnswer_1": "Gene therapy to inhibit LDL receptor expression in hepatocytes using CRISPR-Cas9 gene editing is under investigation to decrease LDL receptor density on the liver cell surface, thereby reducing hepatic LDL uptake and intentionally raising plasma LDL cholesterol levels in patients with acquired hypocholesterolemia.",
                        "wrongAnswer_2": "Gene therapy to enhance PCSK9 expression in hepatocytes using lentiviral vectors is under investigation to increase PCSK9 secretion from the liver, thereby promoting LDL receptor degradation in lysosomes and intentionally lowering plasma LDL cholesterol levels as a novel therapeutic strategy.",
                        "wrongAnswer_3": "Gene therapy to inhibit ABCA1 expression in macrophages using retroviral transduction is under investigation to decrease ABCA1-mediated cholesterol efflux from macrophage foam cells, thereby reducing reverse cholesterol transport and unintentionally lowering plasma LDL cholesterol levels as a side effect.",
                        "wrongAnswer_4": "Gene therapy to enhance CETP expression in hepatocytes using plasmid DNA delivery is under investigation to increase CETP activity and promote the transfer of cholesteryl esters from HDL to LDL, thereby intentionally lowering plasma HDL cholesterol levels and indirectly reducing LDL cholesterol concentrations through lipoprotein remodeling."
                    }
                ]
            }
        ],
        "team_name": "Bob\u00f3kocka"
    }
}
